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rflelomeres are genetic elements that cap and protect the ends
of all chromosomes in eukaryotic cells, and are thereftre.
..L essential for chromosome stability. Telomerase, a ribonu
cleoprotein enzyme complex, is a specialized reverse transcriptase
that functions to complete the replication of telomeres in dividing
cells. Telomerase is composed of an essential RNAcomponent (TR),
which serves as a template during telomere replication, and an es
sential catalytic component called telomerase reverse transcriptase
(TERT)(Figure I). Most somatic cells in humans lack telomerase,
and consequently telomeres shorten to some degree during aging
in nearly all tissues comprised of mitotically active cells. On the
other hand, telomerase is activated during pathogenesis of most
cancers, allowing completion of telomere replication in these cells.
Thus enhanced expression of telomerase in somatic cells has been
proposed as an anti-aging therapy, whereas inhibition of telomerase
in cancer cells has been proposed as a therapy for cancer treatment.
Here I review the pros and cons of telomerase with regard to these
potential therapeutic applications.
The physiological role of telomerase
The main function of telomerase is to complete telomere replication
in the germ line (see figure). This has been proven in mice strains
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in which either the TR gene or TERT gene has been knocked out.
Propagation of either the TR—/- or TERT-!— mice strain leads to
continuous telomere erosion with each successive generation until.
after three to live generations. depending on the strain, the loss of a
telomere from one or more ehromosomal ends becomes prevalent.
The consequence is telomere dysfunction and cell cycle arrest at
the cellular level, and an accelerated aging phenotype including
sterility at the organismal level.
Telomerase also functions to slow the rate of telomere shortening
in tissues with a relatively high turnover rate. This is primarily sup
ported by analysis of telornere shortening during replicatis e aging
of hematopoietic stem cells HSC) from wild-type and telomerase
delieient mice. ilomeres do shorten during replicative aging of
the hematopoietie system, including HSC, in wild-type mice (and
humans). despite the presence of telomerase activity at readily de
tectable levels in these cells. However. hematopoietic cells, includ
ing HSC. from early generation TR—,- or TERT—!- mice have been
shown to have a roughly two—fold increase in the rate of telomere
shortening and a markedl reduced replieative capacity relative to
wild-type mice .
Finally, evidence is now emerging that suggests TERT may have
a telomere-independent function in promoting cell survival in re
sponse to stress. For example, a transgenic model system has been
developedto allow over-expression ofTERT in basal keratinocytes5.
These TERT transgenic mice exhibit enhanced wound healing ea
paeitv relative to svild—tvpe mice. This is unlikely to be a result of
telomere length maintenance in proliferating cells at the site ot the
wound since inbred mice have unusually long telomeres.
Telomerase and cancer
In humans, interestingly, telomerase was first detected in cancer
cells (HeLa cells>, not normal somatic cells6. Indeed, with the
advent of the highly sensitive PCR-based TRAP assay for detec
tion of telomerase activity, high throughput analysis of thousands
of different tumor samples has demonstrated that >9OCf of human
cancers express telomeras& As in germ line cells, the activation of
telomerase in cancer cells allows these cells to acquire replicative
immortality. This was first shown during transformation of human
embryonic kidney cells with SV4O large T antigen, where the rare
emergence of immortal transformed colonies was shown to coincide
with the activation of telomerase and telomere length maintenance6.
We now know that one of the prirnar\ mechanisms for telomerase
activation in caneereells isthe transcriptional activation ofthe TERT
gene. In humans. most cells express moderate to low lex els of TR.
but no detectable levels of T ERT. Furthermore. telomerase can be
fully activated and telomeres elongated in various normal human
somatic cells in vitro simply by the ectopic expression of TERT9,
Two important conclusions may be drawn from this data. First,
telornerase may he a very attractive candidate for cancer therapy.
Preliminary studies have slms n that inacti ation of telomerase in
vitro and in animal models leads to replieative arrest and/or death
of tumor cells and loss of turnorigenieity in vivo1. Second. new
targets for cancer therapy may emerge from a better understanding
of the regulation of TERT expression.
More recently, data has emerged to suggest that telomere-in
dependent functions of TERT may promote cancer development
as well. This is evidenced by studies utilizing transgenic mice in
which TERT over-expression in keratinocytes or blood cells leads
to the predisposition or development of skin eancer or lvmphomas
Allsopp and Weissman. unpublished observations> respeetis ely.
Telomerase: Fountain of youth or cat&yst of
death?
Clearly, telomerase plays an important role in the survival of most
types of cancer, and thus extreme caution is warranted in the use of
telomerase. or more specifically. TERT. as a therapy to rejuvenate
old cells. On the other hand, there is no direct evidence to date to
suggest that telomerase activation per se (ie. ectopic expression of
TERT) predisposes human cells to a cancer phenotype. Transgenic
studies in mice very often cannot be directly extrapolated to humans
due to fundamental differences in biology. In particular, it is well
established that mice cells are more easily transformed than human
cells. Furthermore, there are significant differences in telomere and
telomerase biology between mice and humans. The transient expres
sion of TERT. under the control of a tightly regulated inducible
promoter. in certain human cell types may very well turn out to be
a safe and efficient way to re-set the replicative clock.
Also. as mentioned above. telomerase and proteins that regulate
telomerase are likely to be useful targets for cancer therapy. How
ever, the role oftelomerase in the germ line and proliferative tissues
should not be ignored in any telomerase-based cancer therapies,
despite the normal phenotype of early generation telomerase knock
out mice. Mice telomeres are, on average, four times longer than
human telomeres. so the development of critically short telomeres
upon inhibition of telomerase will be much quicker in humans than
mice Accurate targeting of any telomerase-based drugs to treat
cancer will be important. In the end, it appears that we may be able
to have our cake and eat it too with telomerase. as long as we are
careful.
For more information on the Cancer Research Center of Hawaii,
please visit our website at www.creh.org.
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Until there’s a cure, there’s the American Diabetes Association.
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